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Stroke remains a leading cause of adult disability in the United States for which few approved treatment options 
exist. Approximately 90% of patients survive the initial insult, 
living an average 6 to 7 years thereafter, with most having 
long-term significant impairments and disability.1 Intravenous 
tissue-type plasminogen activator was approved in the United 
States for treatment of acute ischemic stroke in 1996, but only 
≈5% of the US patients receive this medication overall,2 and 
25% in specialized centers3; approximately half of those have 
long-term disability despite treatment.4,5
In the search for additional approaches to improve func-
tion and reduce disability after stroke, attention has been paid 
to restorative therapies.6 One such approach revolves around 
promoting axon outgrowth to augment brain repair. A key rea-
son as to why axons do not regenerate after central nervous 
system injury is the lack of a permissive growth environment. 
Several growth inhibitors have been identified: myelin-asso-
ciated glycoprotein (MAG), oligo-myelin glycoprotein, and 
Nogo-A. One potential strategy is to block the effect of these 
inhibitors.7
The current study pursued this strategy by using a 
monoclonal antibody, GSK249320, which is directed against 
MAG. GSK249320 is a humanized IgG1 monoclonal 
antibody to MAG that has a disabled Fc region; these features 
mitigate concerns related to (1) anti-MAG neuropathy, which 
is attributable to IgM-type antibodies, and (2) toxicity caused 
by activation of Fc-effector functions (eg, activation of 
complement attributable to C1q binding).
This specific approach was motivated by previous reports. 
After stroke in the aged brain, levels of MAG are prominently 
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and spontaneously induced.8 Preclinical studies support the 
hypothesis that blockade of MAG promotes axonal growth, 
such as by introducing a dominant-negative form of the recep-
tor, addition of an anti-MAG antibody, MAG immunodeple-
tion, and inactivation of downstream effectors.9–11
GSK249320 was found in preclinical studies to cross the 
blood–brain barrier (unpublished data, GlaxoSmithKline, 
2013), neutralize MAG-mediated inhibition, promote axonal 
growth, and to protect oligodendrocytes from oxidative stress 
death.12 Studies in rodents and primates indicate that intra-
venous GSK249320 administration beginning 24 hours after 
experimental stroke improves behavioral outcome, without 
changing infarct volume (unpublished data). A study in 47 
healthy human volunteers found no safety concerns with a sin-
gle intravenous infusion up to 25 mg/kg GSK249320.13 Based 
on these findings, a study was initiated in stroke patients with 
primary objective to evaluate the safety and tolerability of 2 
repeat intravenous infusions of GSK249320. Secondary objec-
tives focused on immunogenicity, pharmacokinetics, biomark-
ers, neurophysiology, and motor function, and provided an 
opportunity to further evaluate the performance of modality-
specific outcome measures,14 such as gait velocity, in a stroke 
trial that enrolled patients during acute hospitalization.
Methods
Study Overview
Patients were screened, consented, randomized to intravenous 
GSK249320 or placebo, and received the first infusion within 72 
hours of stroke onset. Multimodal testing was repeated over 112 days. 
All studies were approved by local institutional review boards.
Entry/Exclusion Criteria
Inclusion criteria included stroke onset 24 to 72 hours before therapy 
initiation; stroke radiologically confirmed as supratentorial and ei-
ther (1) ischemic, with diameter >15 mm or volume >4 cc, or (2) 
intracerebral hemorrhage; NIHSS score of 3 to 21 (7–21 in Canada); 
weakness in arm (NIHSS Q5 score 1–3) or leg (NIHSS Q6 score 1–3) 
or both; age 18 to 90 (18–85 in Germany) years; and reasonable like-
lihood of receiving standard physical, occupational, and speech reha-
bilitation therapy. Exclusion criteria included unresponsive (NIHSS 
Q1a score >1); aphasia severe enough to confound evaluations; previ-
ous symptomatic stroke within 3 months; significant prestroke dis-
ability (modified Rankin Scale [mRS]>2); symptomatic depression; 
prestroke symptomatic peripheral neuropathy; prestroke neurological 
or psychiatric disease likely to confound clinical evaluations; previ-
ous demyelinating disease; other major chronic comorbidities; con-
traindication to transcranial magnetic stimulation (TMS) or MRI; 
ECG QTc >500 ms; concomitant participation in any investigational 
rehabilitation paradigm targeting stroke recovery; and pregnancy or 
lactation. Note that subsequent to the first 945 screen failures, entry 
criteria for total National Institutes of Health score, stroke subtype, 
and age were loosened to the above.
Intervention
Each patient was randomized to receive 2 intravenous infusions of 
either GSK249320 or placebo. Infusion 1 was given 24 to 72 hours 
after stroke onset, based on the fact that GSK249320 demonstrated 
the best functional recovery in animal models of stroke when first 
administered 24 hours after stroke. Infusion 2 was given 9±1 days 
after infusion 1 to match details of preclinical studies. Each infusion 
was administered over 60 minutes.
There were 3 sequential dose cohorts (1, 5, and 15 mg/kg), with 
8 patients on active and 8 patients on placebo in cohort 1, and 8 pa-
tients on active and 4 patients on placebo in cohorts 2 and 3. Infusions 
were blinded; however, this trial is considered single-blind because 
the pharmacists preparing the infusions were unblinded to treatment 
allocation. Drug dose levels were selected based on animal data and 
first time in human data.
Study Assessments
Patients were followed for a minimum of 112 days and attended 7 vis-
its during this time (days 1, 5, 10, 30, 60, 90, and 112). The primary 
outcome measure was safety, determined from adverse events, vital 
signs, physical and neurological examination, ECG, nerve conduction 
tests, brain MRI, and clinical laboratory testing. Secondary outcome 
measures included immunogenicity, based on serum measures of an-
ti-GSK249320 antibodies; pharmacokinetics, based on blood draws; 
serum S100β as a biomarker of neural damage, oligodendrocyte pro-
tection, and blood–brain barrier disruption; measures of impairment 
and function; and neurophysiology, based on TMS measures.
Baseline assessments acquired before the first infusion included 
physical and neurological examination; vital signs; clinical labora-
tory testing; blood draw for immunogenicity, biomarker, and phar-
macokinetics; ECG; NIHSS scoring; grip strength testing; Box and 
Blocks testing; and brain MRI. The safety measures of physical and 
neurological exams, vital signs, review of adverse events and con-
comitant medications, laboratory testing, and ECG were acquired 
serially through day 112; nerve conduction testing through day 30; 
brain MRI through day 60; and TMS through day 112. Three glob-
al end points (NIHSS,15 mRS,16 and Barthel Index)16 were assessed 
through day 90; 6 modality-specific end points (gait velocity,17 Fugl-
Meyer arm motor scale,18 Fugl-Meyer leg motor scale,18 bilateral Box 
and Blocks test,19 Berg balance,20 and bilateral grip strength testing)21 
were assessed through day 112; and Geriatric Depression Scale22 and 
Montreal Cognitive Assessment were assessed through day 90; va-
lidity has been established in stroke for each of these assessments 
except for Montreal Cognitive Assessment. Blood samples for im-
munogenicity and pharmacokinetics were acquired through day 112. 
Biomarker samples were acquired on days 1 and 5.
To reduce variance in outcome measures, all scorers were trained 
before study initiation. Training videos were provided for the Berg 
balance and Fugl-Meyer motor scales. TMS procedures and analysis 
were standardized across sites. Formal certification was required for 
mRS and NIHSS.
Data Analysis
Adverse events and other safety parameters were tabulated and exam-
ined. Estimates of the effect of GSK249320 at each dose relative to 
placebo were calculated for motor function and global end points. A 
repeated measures model was fitted, with treatment, visit, treatment 
X visit interaction, and baseline as fixed effects. Visit was fitted on the 
repeated statement. Scores on mRS were analyzed at each visit using 
χ2 testing. Montreal Cognitive Assessment and Geriatric Depression 
Scale at day 90 were analyzed using analysis of covariance, with 
treatment as the fixed effect and day 5 score as a covariate. The rela-
tionships between GSK249320 plasma exposures and any markers of 
safety or biological activity were subjected to exploratory pharmaco-
kinetic/pharmacodynamic analyses. Study MRI scans were reviewed 
by an experienced neuroradiologist at the GlaxoSmithKline Clinical 
Imaging Center, including measurement of infarct volume on acute 
diffusion-weighted images. For analysis of pharmacokinetic data, an 
initial assessment of dose proportionality was explored for the area 
under the curve from time zero (predose) extrapolated to infinite 
time, area under the curve from time zero to last time of quantifiable 
concentration within a subject across all treatments, and maximum 
observed concentration (Cmax) using graphical presentations. An as-
sessment of dose proportionality was made.
Enrollment was planned at 40 patients based on safety, feasibility, 
and the need to provide sufficient placebo-treated subjects to 
characterize the outcome measures in terms of variability and placebo 
response. Two additional subjects were enrolled in cohort 2 as per 
protocol after withdrawal of subjects in cohorts 1 and 2, increasing total 
enrollment to 42. Missing data were not imputed. Data management 
responsibilities and statistical analyses were handled by GSK.
Figure 1. CONSORT diagram.
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Results
Study Conduct
A total of 3359 patients were screened, with the most com-
mon reason for screen failure being a non-stroke (for exam-
ple, transient ischemic attack instead). A total of 42 subjects 
were enrolled, all of whom received ≥1 dose of investigational 
product and had the first infusion 24 to 72 hours after stroke as 
planned, and 38 (90%) subjects received both doses of inves-
tigational product (Figure 1). The treatment blind was acci-
dently broken for 1 subject during the study (15 mg/kg group) 
on day 11. All strokes were ischemic apart from 1 patient in 
the 15 mg/kg group with hemorrhagic stroke. Baseline char-
acteristics were similar across treatment groups (Table 1). 
Thirty-six (86%) subjects completed the study, and 6 (14%) 
subjects withdrew from the study prematurely. One subject 
in the GSK249320 15 mg/kg group was withdrawn because 
of investigator discretion. Five subjects (3 placebo, 1 in the 5 
mg/kg group, 1 in the 15 mg/kg group) withdrew consent, 2 
because of medical worsening and 3 for personal reasons (eg, 
doing too well or did not have time). No subjects were with-
drawn because of an adverse event. The amount of physical 
therapy, occupational therapy, or total therapy did not signifi-
cantly differ between treatment arms at any time point.
There were 5 protocol deviations: a subject with active 
depression was enrolled (5 mg/kg group), infusion 2 was 
given to a subject (5 mg/kg group) 2 days beyond the allow-
able protocol window, and a dosing error for a subject (5 mg/
kg group) resulted in that subject receiving a 1 mg/kg dose 
for the first administration. Additionally, 2 subjects received 
an excess amount of investigational product (1 in the placebo 
group and 1 in the 5 mg/kg group). Nothing suggested an 
adverse effect of these events on safety findings.
Safety
GSK249320 was generally well tolerated. No clinically signifi-
cant trends were present in heart rate, systolic blood pressure, 
or diastolic blood pressure after dosing, with similar patterns 
present across treatment groups. Overall, an adverse event was 
reported in 31 (73.8%) subjects, most commonly insomnia, con-
stipation, pyrexia, and diarrhea; and this did not vary according 
to treatment group. A serious adverse event was reported in 10 
(23.8%) subjects, which also did not vary by treatment group 
and was as expected for the patient population; none was fatal. 
Three events were deemed potentially drug related by the local 
investigator: 2 were in the same patient (15 mg/kg group), con-
sisting of acute renal failure (mild intensity, days 18–38) and 
stroke (moderate intensity, days 38–58), and the third was an 
event of dysgeusia reported in a patient in the 5 mg/kg group. 
There were no events suggestive of infusion site reactions, 
allergic or hypersensitivity reactions, or peripheral or central 
demyelination with GSK249320 treatment. No adverse event 
resulted in discontinuation of drug. Events common to stroke 
were tabulated separately, present in 66.7% of subjects, and did 
not vary according to treatment group; the most common events 
were depression/mood disorder and joint or soft tissue pain.
Laboratory Results
No clinically significant trends were observed for postdosing 
clinical chemistry and hematology parameters, which were 
similar across treatment groups. ECG findings also evolved 
over time similarly across groups. Nerve conduction testing 
found no suggestion of peripheral demyelination related to 
GSK249320. TMS found no results that might suggest clinical 
worsening among subjects who received GSK249320, and 
will be presented in detail elsewhere. MRI review raised no 
concerns, including no suggestion of increased risk of central 
demyelination secondary to GSK249320 treatment.
Figure 1. CONSORT diagram.
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Biomarker Results
Levels of the S100β protein were detectable in all subject 
samples at all time points. No significant change in S100β 
levels over time was apparent in any of the 4 subject groups, 
however, and levels did not differ between placebo- and 
GSK249320-treated subjects. There was a trend for higher 
serum levels of S100β in relation to NIHSS score at baseline 
(ρ=0.29; P=0.089).
Pharmacokinetic Results
Pharmacokinetic analysis of subjects who received GSK249320 
and blood sampling per protocol found that the geometric 
mean of terminal half-life across all subjects was 22.5 days. 
GSK249320 plasma concentrations were linear with increasing 
dose for the area under the curve and for Cmax, after both first 
and second drug administration. The initial volume of distribu-
tion was 30.5 mL/kg, the volume of distribution at steady state 
was 54.8 mL/kg, and clearance was 0.0757 mL/kg per hour.
Immunogenicity Results
Of the 25 subjects who were dosed with GSK249320, 2 (8%) 
developed transient antidrug antibodies after infusion 1 (1 in the 
1 mg/kg group and 1 in the 5 mg/kg group). In addition, 1 sub-
ject had preexisting antibodies, with a titer of 600, that were only 
present in the day 1 predose sample collection and consequently 
not related to treatment. None of the immunogenicity-positive 
responses were associated with alterations in the pharmacoki-
netic profile or adverse event findings.
Clinical Outcome
There were no apparent trends suggestive of clinical worsening 
in subjects receiving GSK249320. NIHSS total scores improved 
over time and did not suggest harm with GSK249320 treatment. 
Findings for the day 90 global outcome measures, NIHSS and 
mRS, did not differ across treatment groups (Table 2).
The modality-specific end points, many of which have not 
been extensively used in stroke trials that enroll patients during 
the acute stroke hospitalization period, could be collected in most 
patients early after stroke. At visit 1, 24 to 72 hours after stroke, 
the first assessment of the Box and Blocks test was obtained in 
all 42 subjects; grip strength test was obtained in 41 subjects. 
For the 41 subjects who received a visit 2 examination, which 
occurred 5 to 9 days after stroke, the first assessment of Fugl-
Meyer scores could each be obtained in 40 subjects; Montreal 
Cognitive Assessment score in 39 subjects; and gait velocity, 
Berg balance, and Geriatric Depression Scale in 38 subjects.
The gait velocity data suggested a trend toward benefit 
with GSK249320 treatment that warrants further explora-
tion in future trials. A mixed model repeated measures analy-
sis of mean change in gait velocity found greater gains for 
GSK249320 (all doses combined) compared with placebo at 
days 30 (P=0.006), 90 (P=0.018), and 112 (P=0.012), largely 
driven by results in the 1 mg/kg and 5 mg/kg groups (Figure 2). 
The only other modality-specific measure to show such a 
finding was the lower extremity Fugl-Meyer score at day 30 
(P=0.027). Note, however, that 5 of the 10 sites that enrolled 
subjects assessed gait velocity incorrectly, with 4 sites 
Table 1. Baseline Characteristics
Placebo 1 mg/kg 5 mg/kg 15 mg/kg
No. subjects randomized 17 8 9 8
Age, y 67.6±10.8 62.1±13.0 63.9±13.8 59.3±13.0
Sex (F/M) 11/6 3/5 5/4 4/4
Previous stroke 12% 0 0 0
Previous TIA 6% 0 11% 13%
Atrial fibrillation 18% 25% 0 13%
Hypertension 94% 88% 67% 75%
Diabetes mellitus 24% 25% 44% 38%
Hypercholesterolemia 53% 38% 33% 38%
Current smoker 24% 63% 33% 25%
Previous myocardial infarct 6% 13% 11% 0
Race
 White 100% 88% 100% 88%
 Asian 0 12% 0 12%
Stroke in MCA territory 94% 100% 67% 88%
Infarct volume, cc 29.4±40.7 20.8±25.1 35.2±50.2 15.6±18.8
Time from stroke onset to first dose, h 55±14 53±16 46±13 46±13
Received acute reperfusion therapy for index stroke 35% 38% 11% 25%
Baseline NIHSS score 7 (3–17) 7.5 (4–14) 7 (4–17) 6 (3–13)
Percentage arm motor deficit at baseline (NIHSS Q5>0) 100% 100% 100% 100%
Percentage leg motor deficit at baseline (NIHSS Q6>0) 88% 88% 89% 50%
IA indicates intra-arterial; MCA, middle cerebral artery; MERCI, Mechanical Embolus Removal in Cerebral Ischemia; NIHSS, National Institute of Health Stroke Scale; 
andTIA, transient ischemic attack.
Results are mean±SD, median (range), or percentage. Acute reperfusion therapy includes intravenous tissue-type plasminogen activator, IA tissue-type plasminogen 
activator, MERCI, and Penumbra. No baseline characteristic varied according to treatment group.
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instructing subjects to walk as fast as possible instead of at a 
normal pace, and 1 site instructing subjects to both walk as fast 
as possible and at a normal pace.
Discussion
Restorative therapies have the potential to be accessed by a 
large percentage of stroke patients and therefore might be use-
ful complements to reperfusion and rehabilitation approaches to 
stroke therapy. One form of restorative therapy aims to improve 
function by promoting axon outgrowth to augment brain repair. 
GSK249320 is a monoclonal antibody that blocks the growth 
inhibiting glycoprotein MAG and protects oligodendrocytes, 
and that was found to improve behavioral outcomes in rodent 
and primate studies. The current study translated GSK249320 in 
accordance with Stroke Therapy Academic Industry Roundtable 
(STAIR) guidelines; in particular, preclinical studies found that 
GSK249320 was associated with significant gains in motor 
recovery compared with placebo in several stroke models, in 
both rodent and primate studies. The current study found that, 
across 3 escalating dose levels, GSK249320 was generally well 
tolerated in human subjects with moderate stroke.
The primary outcome measure was safety, and all 3 dose 
levels of GSK249320 performed well in this regard. Review 
of adverse events, vital signs, physical and neurological 
exams, ECG, nerve conduction tests, brain imaging, clinical 
outcomes, and laboratory studies did not disclose any con-
cerns. One theoretical concern was induction of demyelin-
ating lesions on introduction of antibodies directed against 
MAG. However, these were not detected in peripheral or 
central nervous system, in accordance with the design of the 
GSK249320 antibody. In addition, GSK249320 was not found 
to be strongly immunogenic or to cause any infusion site reac-
tions, allergic responses, or hypersensitivity reactions.
Pharmacokinetic data demonstrated the half-life of 
GSK249320 in stroke patients to be similar to the 21 days 
estimated in healthy volunteers13 and typical of an IgG1 type 
of monoclonal antibody. The linearity with dose observed in 
the healthy volunteer study was also confirmed in this stroke 
patient study. Furthermore, population analyses showed lim-
ited variability and good agreement with the parameter esti-
mates in the healthy volunteer study.
S100β is a glial cell marker secreted from disrupted 
oligodendrocytes in ischemic tissue23 and was included in 
the current study to assess the oligodendrocyte protection 
properties23 of GSK249320, neurological damage, and blood–
brain barrier dysfunction.24 Oligodendrocyte protection is 
relevant to stroke recovery; for example, oligodendroctye 
integrity is important to the function of new axon sprouts as 
well as axons that lose myelin during ischemia.25 Detection of 
S100β in all serum samples across groups suggests consistent 
blood–brain barrier leakage across subjects. However, S100β 
levels did not increase over the measurement period, as 
reported previously,24 possibly because of sampling of S100β 
at relatively late time points in the current study. Because no 
reduction in serum S100β levels was demonstrated in relation 
to GSK249320 treatment and no differences in serum S100β 
levels were observed between placebo- and GSK249320-
treated patients, verification of the oligodendrocyte protection 
mechanism of GSK249320 could not be concluded in the 
current study. The trend toward increasing serum S100β levels 
with greater stroke severity is consistent with previous reports.24
Secondary outcome measures also included both global 
and modality-specific outcome measures. Global outcome 
Table 2. Final Outcome Measure Results
Placebo 1 mg/kg 5 mg/kg 15 mg/kg
Global outcome measures
NIHSS score 2.0 1.5 2.5 1.0
Percentage modified Rankin Scale score 0–1 21% 25% 38% 33%
Barthel Index 95 100 100 80
Modality-specific outcome measures
Fugl-Meyer leg motor scale 25.2±10.0 25.0±9.5 31.4±3.5 25.5±13.8
Fugl-Meyer arm motor scale 48.7±24.5 46.5±27.1 52.1±18.0 37.7±31.0
Box and Blocks test 22.9±14.9 25.3±22.4 31.3±20.7 25.8±24.1
Berg balance 41.8±19.4 50.3±7.0 50.4±10.0 35.7±23.4
Grip strength 15.6±14.5 18.1±20.6 17.1±11.5 17.6±19.7
Values are mean±SD, except for the NIHSS and Barthel Index, which are median. The Fugl-Meyer leg motor scale ranges from 0 to 34; the Fugl-Meyer arm motor 
scale ranges from 0 to 66; the Berg Balance scale ranges from 0 to 56; for each of these scales, a higher score is better. The Box and Blocks score is the number of 
blocks transported by the affected upper extremity in 60 s. Grip strength is reported in kg.
Figure 2. Gait velocity is provided over the 112 days of study 
conduct for each of the 4 treatment groups. The change in gait 
velocity was significantly greater for GSK249320 compared with 
placebo at days 30 (P=0.006), 90 (P=0.018), and 112 (P=0.012), 
driven by 1 mg/kg and 5 mg/kg group results.
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measures (Table 2) were similar across treatment groups and, 
in general, were as expected for a study of moderate stroke. 
The 6 modality-specific end points,14 each of which has estab-
lished validity in the setting of stroke17–21 and many of which 
have not been commonly used in the acute stroke setting,26 
could be consistently collected in the first days after stroke, 
although patients with severe aphasia were excluded. One rea-
son for including modality-specific secondary outcome mea-
sures was that some of these approximated the motor-intensive 
behavioral end points used in the preclinical studies. The 
results suggest a potentially favorable effect of GSK249320 
on gait velocity (Figure 2), a measure of lower limb motor 
recovery, and on lower extremity motor Fugl-Meyer, a mea-
sure of sensorimotor function. Both findings might reflect type 
I error and require validation. However, half of the sites did 
not collect gait velocity data correctly, despite clear testing 
details in the procedures manual and protocol, indicating that 
this detail was not fully assessed at site initiation visits, and 
highlighting the importance of training for novel end points.
Restorative therapies in the acute stroke setting generally 
have a time window of a day or more and therefore have the 
potential to improve outcome in a large percentage of patients. 
The current study found that 2 intravenous infusions of one such 
therapy, GSK249320 initiated 24 to 72 hours after stroke onset, 
is well tolerated. This is a novel approach to brain repair after 
stroke because there is limited experience using a monoclonal 
antibody to modify poststroke neurobiology in humans. The cur-
rent results support the safety of this pharmaceutical compound 
and the value of further studies in patients with acute stroke.
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